

Nurosene Initiates Research on Nuro App in Collaboration with Dalhousie University

Nurosene, in partnership with Canada's National Research Council IRAP program and Dalhousie University's BIOTIC Research Centre in Halifax, Canada, has conducted preliminary research on the Nuro App leveraging modern brain imaging technologies, including functional magnetic resonance imaging (fMRI).

TORONTO, April 19, 2022 /CNW/ - [Nurosene Health Inc.](#) ("Nurosene" or the "Company") (CSE: MEND) (Frankfurt: 8TV) (OTC: MNNDNF), a healthtech company focused on delivering innovative AI-based technology solutions for mental performance and wellness, announces that it has received funding from Canada's National Research Council IRAP program to conduct research on the Nuro App in collaboration with Dalhousie University.

The Nuro App was designed by our team of neurological experts, who have been working in clinics and performance centers with elite professional athletes and complex neurological cases for decades. The goal of the mobile app is to provide users with quick and efficient field-tested exercises focused on helping users improve mental performance, reduce burnout and drive resiliency.

"The Nuro App is taking steps to revolutionize mental health, wellness, and brain performance by peering deeper into the brain with the goal of connecting these findings with the community at scale. Modern brain imaging technologies, such as fMRIs, can look into the brain to help uncover the mysteries of human performance, behavior, illness, and disease in a way that was simply not possible even a generation ago." said Daniel Gallucci, Chief Innovation Officer and Co-Founder.

This partnership with Canada's National Research Council IRAP program and Dalhousie University's BIOTIC Research Centre, has enabled Nurosene to begin preliminary research validation on brain activity elicited through their Nuro App. These modern brain imaging techniques enable us to dive deeper by looking at the structure and function of the brain in real time.

This research is allowing us to provide an objective measurement of brain activity through functional magnetic resonance imaging (fMRI), where we can non-invasively image changes in blood flow throughout the brain during the performance of tasks that mimic those in the Nuro App. These scans are able to provide us with a better understanding of the brain-based biological underpinnings of health and disease, as well support with the future direction of the Nuro App.

We will continue this research project through additional validation and research studies as we continue to evolve and enhance the Nuro App.

About Nurosene

Nurosene is a healthtech company focused on delivering innovative AI-based technology solutions that support mental performance and wellness. Our mission is to build healthier, more productive brains by leveraging our cutting-edge technology. Our world-renowned team and partners are disrupting traditional mental wellness treatments and are positioned at the forefront of critical

research and innovations. NetraMark, a wholly owned subsidiary of Nurosene Health Inc., is providing proprietary next-generation AI solutions for pharmaceutical and biotechnology companies across the spectrum of disease.


For more information, visit www.nurosene.com.

Forward-Looking Statements

This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation which is based upon Nurosene's current internal expectations, estimates, projections, assumptions and beliefs, and views of future events. Forward-looking information can be identified by the use of forward-looking terminology such as "expect", "likely", "may", "will", "should", "intend", "anticipate", "potential", "proposed", "estimate" and other similar words, including negative and grammatical variations thereof, or statements that certain events or conditions "may", "would" or "will" happen, or by discussions of strategy. Forward-looking information includes estimates, plans, expectations, opinions, forecasts, projections, targets, guidance, or other statements that are not statements of fact. Specifically, this news release contains forward-looking statements relating to, among others, activities of the Company's mobile application (the "Nuro App") and research through a partnership between the Company, Canada's National Research Council IRAP program and Dalhousie University's BIOTIC Research Centre including potential results, uses and the impact of the research including the identification of treatments, the importance of the research, possible enhancements to our technology, growth and other initiatives thereto.


Any forward-looking information speaks only as of the date on which it is made, and, except as required by law, Nurosene does not undertake any obligation to update or revise any forward-looking information, whether as a result of new information, future events, or otherwise. New factors emerge from time to time, and it is not possible for Nurosene to predict all such factors. When considering these forward-looking statements, readers should keep in mind the risk factors and other cautionary statements in Nurosene's Final Long Form Prospectus dated May 20, 2021 and Management's Discussion and Analysis for the year ended September 30, 2021 ("MD&A"), and filed with the applicable Canadian securities regulatory authorities on SEDAR at www.sedar.com. The risk factors and other factors noted in Nurosene's Final Long Form Prospectus and MD&A could cause actual events or results to differ materially from those described in any forward-looking information.

The CSE does not accept responsibility for the adequacy or accuracy of this release.



Example activation map for the breath hold task. Red voxels indicate locations where the fMRI signal's correlation with the task block design is significant ($p < 0.05$). (CNW Group/Nurosene Health Inc.)

SOURCE Nurosene Health Inc.

 View original content to download multimedia:

<http://www.newswire.ca/en/releases/archive/April2022/19/c2214.html>

%SEDAR: 00050449E

For further information: Blake Sing, Chief Financial Officer, investors@nurosene.com; (416) 859 8838

CO: Nurosene Health Inc.

CNW 09:54e 19-APR-22